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ABSTRACT 
RATIONALE: We have previously demonstrated that experimental pneumococcal carriage enhances 
immunity and protects healthy adults against carriage reacquisition following re-challenge with a 
homologous strain. Here we have used a heterologous challenge model to investigate the role of 
naturally acquired pneumococcal protein and polysaccharide (PS)-specific immunity in protection 
against carriage acquisition.  
METHODS: We identified healthy volunteers that were naturally colonised with pneumococcus and, 
following clearance of their natural carriage episode, challenged them with a heterologous 6B strain. 
In another cohort of volunteers we assessed 6BPS-specific, PspA-specific and PspC-specific IgG and 
IgA plasma and memory B-cell populations prior to and 7, 14 and 35 days following experimental 
pneumococcal inoculation. 
RESULTS: Heterologous challenge with 6B resulted in 50% carriage among volunteers with previous 
natural pneumococcal carriage. Protection from carriage was associated with a high number of 
circulating 6BPS IgG-secreting memory B-cells at baseline. There were no associations between 
protection from carriage and baseline levels of 6BPS IgG in serum or nasal wash, PspA-specific or 
PspC-specific memory B-cells or plasma cells. In volunteers who did not develop carriage, the 
number of circulating 6BPS memory B-cells decreased and the number of 6BPS plasma cells 7 days 
post inoculation.  
CONCLUSIONS: Our data indicate that naturally acquired polysaccharide-specific memory B-cells, 
but not levels of circulating IgG at time of pneumococcal exposure, are associated with protection 
against carriage acquisition. 
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INTRODUCTION 
Pneumococcal carriage is a pre-requisite of infection and the primary reservoir for transmission (1, 
2). Carriage is also an important immunising event in healthy adults and we have previously 
demonstrated that experimental carriage protects against reacquisition of carriage after 
reinoculation with the same strain (homologous) for up to eleven months following clearance of the 
first carriage episode (3).  
Animal models have demonstrated that immunoglobulins play a role in host defence against carriage 
acquisition (4) and IL-17 secreting CD4
+
 T-cells play a role in the clearance of carriage (5). While 
these immunological responses are well described in murine models, the immunological responses 
which mediate protection in humans have not been identified. We have previously observed that 
pneumococcal colonisation increases the level and functional capacity of pneumococcal-specific IgG 
and IgA in serum and nasal wash, and that colonisation also increases the number of pneumococcal-
specific IL-17 secreting CD4
+
 T-cells in the lung (3, 6, 7).  
Epidemiological data supports the role of polysahccaride (PS)-mediated immunity in protection 
against carriage. Vaccination with pneumococcal conjugate vaccine (PCV) has reduced carriage of 
vaccine type strains (8), and has resulted in serotype replacement in vaccinated communities (9, 10). 
We have recently demonstrated the direct impact of PCV vaccination on pneumococcal carriage 
acquisition (11). In a double-blind randomised control trial, the rate of carriage acquisition, following 
challenge with 6B pneumococcus, was reduced by 78% in PCV vaccinated volunteers compared with 
control vaccinated volunteers. We have previously demonstrated that baseline levels of both PS-
specific IgG and capacity for opsonphagocytic killing did not predict carriage outcome following 
intranasal pneumococcal inoculation (3, 6, 12). 
PS-specific memory B-cells (BMEM) are not present in the mucosal immune tissue of the human 
nasopharynx (13). This suggests that the localised stimulation and differentiation of BMEM into plasma 
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cells (BPLAS) is unlikely to occur in situ at the mucosa, and that PS-specific immunoglobulin from 
systemic circulation may instead mediate protection against carriage acquisition at the mucosal 
surface.  
Here we identified healthy volunteers that were naturally colonised with pneumococcus and 9 to 16 
months following clearance of their carriage episode challenged them with a heterologous 
pneumococcal serotype, resulting in a 50% rate of carriage. We have previously demonstrated 0% 
carriage reacquisition up to 11 months following a carriage episode when re-challenged with the 
same strain (3). We further assessed B-cell-mediated immunity among volunteers with no current 
pneumococcal carriage and an unknown history of previous pneumococcal carriage exposure. We 
observed that volunteers protected from carriage (carriage-negative) had similar levels of circulating 
IgG but higher number of PS-specific BMEM than volunteers susceptible to carriage (carriage-positive). 
Responses to protein-based antigens were not associated with protection against carriage. Taken 
together these data suggest that naturally acquired PS-specific immunity plays a prominent role in 
mediating protection against acquisition of pneumococcal carriage in unvaccinated volunteers. 
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MATERIALS AND METHODS 
Ethical approval, study protocol and sampling 
8 healthy non-smoking adult volunteers aged between 18 and 60 years, who had a confirmed 
previous natural carriage episode, and who had no close contact with risk individuals were recruited 
to cohort A. 24 healthy non-smoking adults aged between 18 and 60 years, who had no current 
pneumococcal carriage and an unknown history of pneumococcal exposure, and who had no close 
contact with at-risk individuals were recruited to cohort B. Written informed consent was obtained 
from all volunteers. Both studies were approved by the National Research Ethics Service 
(11/NW/0592) and were sponsored by the Royal Liverpool and Broadgreen University Hospitals 
Trust.  
In cohort A, each volunteer was inoculated with 35375 ± 2651 colony-forming units (cfu) per naris of 
S. pneumoniae serotype 6B (strain BHN418) (14) (Table 1). In cohort B, each volunteer was 
inoculated with 61944 ± 4603 cfu/naris of S. pneumoniae serotype 6B (Table 1). Bacterial 
preparation and inoculation, as well as nasal wash sampling and carriage detection were performed 
as previously described (15). In cohort A, nasal wash samples were obtained 5 days prior to 
intranasal inoculation and then on days 2, 7 and 14 following inoculation. Peripheral blood samples 
were obtained 5 days prior to intranasal inoculation and then 14 days following inoculation. In 
cohort B, nasal wash samples were obtained 5 days prior to intranasal inoculation and then on days 
2, 7, 14, 21, 28 and 35 following inoculation. Peripheral blood samples were obtained 5 days prior to 
intranasal inoculation and then on days 7, 14 and 35 days following inoculation.  
Anti-pneumococcal capsular polysaccharide ELISA 
Anti-pneumococcal capsular polysaccharide (PS) antibodies were determined using the World Health 
Organisation internationally standardised method and reagents (16). For full details, please refer to 
Supplementary Materials and Methods. 
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Opsonophagocytic killing assay (OPKA) 
OPKA assays were performed as previously described(3), with minor modifications. For full details, 
please refer to Supplementary Materials and Methods. 
Preparation of Enzyme-linked immunosorbent spot (ELISpot) plates 
Wells of ELISpot plates (multiscreen IP 96-well filter plates; Millipore) were coated with 100µL 
Dulbecco's PBS
-/-
 (DPBS) supplemented with either anti-IgG (1:50; total IgG), anti-IgA (1:50; total IgA) 
20µg/mL 6BPS, 2µg/mL PspA, 2µg/mL PspC, influenza (1:50; positive control, unpublished data) or 
unsupplemented DPBS (negative control). Coated plates were stored at 4˚C for up to 48 hours. 24 
hours prior to use, ELISpot plates were brought to room temperature and washed six times with 
DPBS. Plates were blocked with RPMI-1640 supplemented with 2% BSA for two hours. Plates were 
then washed six times with DPBS. 
Plasma cell (BPLAS) detection 
Peripheral blood mononuclear cells (PBMCs) were isolated using Histopaque®-1077 (Sigma-Aldrich), 
according to the manufacturers instructions. For full details, please refer to Supplementary Materials 
and Methods. Cells were seeded in ELISpot plates in 100µL volumes, in complete medium, in 
triplicate, at a concentration of either 5 × 10
6
 cells/mL (6BPS, PspA, PspC) or 5 × 10
5
 cells/mL (total 
IgG, total IgA, positive control, negative control). Plates were incubated for sixteen hours at 37°C in 
5% CO2. For detection of IgG, plates were washed six times with 0.05% PBS-tween and incubated 
with 1:2,000 anti-human-IgG-alkaline-phosphatase (Sigma-Aldrich) for two hours. For detection of 
IgA, plates were washed six times with 0.05% PBS-tween and incubated with 1:2,000 anti-human-IgA 
(AbD Serotec) for two hours. Plates were then washed a further six times with 0.05% PBS-tween and 
incubated with 1:2,000 streptavidin:alkaline phosphatase (AbD Serotec) for one hour. For detection 
of both IgG and IgA, plates were washed six times with 0.05% PBS-tween and incubated with 100µL 
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p-nitrophenyl phosphate (pNPP; Sigma-Aldrich). Plates were washed six times with distilled H2O and 
then stored in the absence of light. 
Memory B-cell (BMEM) detection 
2.5 × 10
6
 cells/mL were seeded in 6-well plates, in complete medium supplemented with 1:2,500 
Staphylococcus aureus Cowan strain (SAC), 1:3,000 pokeweed mitogen (PWM; Sigma-Aldrich), and 
1:40 CpG oligonucleotide (ODN-2006; TCG-TCG-TTT-TGT-CGT-TTT-GTC-GTT; InvivoGEN). Plates were 
incubated for seven days at 37°C in 5% CO2. Cells were harvested, washed in complete medium and 
the cell concentration determined using an Improved Neubauer Haemocytometer (CamLab). Cells 
were then seeded in ELISpot plates in 100µL volumes, in complete medium, in triplicate, at a 
concentration of either 5 × 10
6
 cells/mL (6BPS, PspA, PspC) or 5 × 10
5
 cells/mL (total IgG, positive 
control, negative control). Plates were incubated for sixteen hours at 37°C in 5% CO2. Plates were 
washed six times with 0.05% PBS-tween and incubated with 1:2,000 anti-human-IgG-alkaline-
phosphatase for two hours. Plates were washed six times with 0.05% PBS-tween and incubated with 
100µL pNPP (Sigma-Aldrich). Plates were washed six times with distilled H2O and then stored in the 
absence of light. 
ELISpot counting 
ELISpot data were acquired using an AID ELISpot Reader (ELR02) and the data analysed using AID 
ELISpot Software v3.3 (Cadama Medical). Identical settings were used for the analysis of all wells. All 
plates were manually verified and any artefacts removed by an operator who was blinded for the 
ELISpot condition, the carriage status of each volunteer and the sampling time point. 
Statistical analyses  
All statistical analyses were performed using SPSS v22 (IBM) and all P values are two-tailed. Where 
appropriate, data were logarithmically transformed for purposes of statistical analyses. Comparisons 
were made between carriage-positive and carriage-negative groups using unpaired t tests; 
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differences were considered significant at P≤0.05. Multiple comparisons were made within carriage-
positive and carriage-negative groups using paired t tests with manual Bonferroni correction 
(significance level α=0.05 with number of tests n=3); differences were considered significant at 
P<0.0166.  
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RESULTS 
Natural episodes of pneumococcal carriage do not protect against heterologous challenge 
In order to determine the role of naturally acquired serotype-specific immunity in protection against 
carriage acquisition we identified a cohort of 8 healthy volunteers (cohort A) that were naturally 
colonised with pneumococcus and, following clearance, experimentally challenged them with a 
heterologous strain.  
We observed that heterologous inoculation with 6B pneumococcus 9 to 16 months following 
clearance of natural carriage resulted in 50% carriage (Table 1 and 2). In another cohort of 24 
volunteers (cohort B), with no current pneumococcal carriage and unknown history of 
pneumococcal exposure, inoculation with 6B pneumococcus resulted in 42%  carriage (Table 1). 
This is consistent with the 40-60% carriage rates observed in our previous studies where uncolonised 
volunteers were inoculated with doses of 6B pneumococcus ranging between 40,000-130,000 
cfu/naris (3).  
Levels of 6BPS IgG and IgA in serum and nasal wash are not associated with protection against 
carriage acquisition 
We assessed levels of pneumococcal antibody and B-cells in cohort B. Levels of 6BPS IgG in serum at 
baseline (day -5) were similar in carriage-positive volunteers (those that were susceptible to 
carriage) and carriage-negative volunteers (those that were protected against carriage) (Figure 1A; 
median [interquartile range (IQR)]: 1.0µg/mL [0.6-1.6] versus 0.9µg/mL [0.5-1.4]). In carriage-
positive volunteers, post inoculation levels of 6BPS IgG were comparable at day 7 (1.1µg/mL [0.6-
2.0]), but were significantly higher at day 14 (1.3µg/mL [0.8-3.8]; P=0.001) and day 35 (2.5µg/mL 
[1.2-5.8]; P=0.001) than at baseline. In carriage-negative volunteers levels of 6BPS IgG in serum 
following inoculation were comparable to those at baseline. Levels of 6BPS IgG in nasal wash at 
baseline were similar in carriage-positive volunteers and carriage-negative volunteers (Figure 1B; 
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1.0ng/mL [0.8-2.4] versus 0.7ng/mL [0.6-0.8]). In both groups levels of 6BPS IgG in nasal wash 
following inoculation were comparable to those at baseline. 
Levels of 6BPS IgA in serum at baseline were higher in carriage-positive volunteers than in carriage-
negative volunteers (Figure S1A; 0.5µg/mL [0.4-0.6] versus 0.3µg/mL [0.2-0.4]; P=0.001). In carriage-
positive volunteers, post inoculation levels of 6BPS IgA were comparable at day 7 (0.5µg/mL [0.4-
0.6]), significantly higher day 14 (0.8µg/mL [0.5-1.9]; P=0.005) but were not significantly higher at 
day 35 (0.7µg/mL [0.5-1.5]) than at baseline. In carriage-negative volunteers levels of 6BPS IgA in 
serum following inoculation were comparable to those at baseline. Levels of 6BPS IgA in nasal wash 
were similar in carriage-positive volunteers and carriage-negative volunteers between both groups 
at baseline (Figure S1B; 18.3ng/mL [12.0-45.0] versus 14.0ng/mL [6.9-16.4]) and were unchanged 
following challenge. 
We assessed whether the capcity of antibodies in mediating phagocytosis was associated with 
protection. No difference was between carriage-negative volunteers compared with carriage-
positive volunteers at baseline (Figure S2).  
High baseline number of 6BPS IgG-secreting BMEM is associated with protection against carriage 
acquisition 
At baseline, the number of 6BPS IgG-secreting BMEM in carriage-positive volunteers was 
approximately three-times lower than that in carriage-negative volunteers (Figure 2A; 12.3 [9.4-
25.4] versus 32.1 [14.9-86.4]; P=0.042). Post inoculation, in carriage-positive volunteers, the 
numbers of 6BPS IgG-secreting BMEM at day 7 (15.0 [4.4-46.8]), day 14 (15.6 [5.4-24.9]) and day 35 
(7.0 [5.6-30.0]) was comparable to those at baseline. In carriage-negative volunteers, the number of 
6BPS IgG-secreting BMEM was not significantly lower at day 7 (8.3 [5.7-16.4]) or day 14 (11.8 [8.4-
26.7]; P=0.03) but was significantly lower at day 35 (5.9 [3.4-11.4]; P=0.012) compared to baseline. 
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At baseline, the number of 6BPS IgG-secreting BPLAS was not different in carriage-positive volunteers 
compared with carriage-negative volunteers (Figure 2B; 3.0 [1.8-37.8] versus 5.3 [0.5-14.9]). Post 
inoculation, in carriage-positive volunteers, the number of 6BPS IgG-secreting BPLAS were not 
significantly different to those at baseline. In carriage-negative volunteers, the number of 6BPS IgG-
secreting BPLAS was approximately four-times higher at day 7 (83.5 [45.6-135.3]; P=0.006) compared 
to baseline, returning to a comparable level at day 14 (3.3 [1.0-9.0]) and day 35 (7.3 [2.5-13.3]). 
Baseline number of PspA and PspC IgG-secreting BMEM are not associated with protection against 
carriage acquisition 
At baseline, the number of PspA IgG-secreting BMEM was not different in carriage-positive volunteers 
compared with carriage-negative volunteers (Figure 3A). In both groups numbers of PspA IgG-
secreting BMEM following inoculation were comparable to those at baseline. 
At baseline, the number of PspA IgG-secreting BPLAS was not different in carriage-positive volunteers 
compared with carriage-negative volunteers (Figure 3B; 25.5 [9.8-36.2] versus 13.8 [4.5-71.8]). Post 
inoculation, in carriage-positive volunteers, the number of PspA IgG-secreting BPLAS was not 
significantly higher at day 7 (50.7 [31.0-84.7]) or day 14 (79.2 [25.8-141.6]) but was significantly 
higher at day 35 (74.8 [67.7-79.6]; P=0.005) compared to baseline. In carriage-negative volunteers 
the numbers following inoculation were comparable to those at baseline. 
At baseline, the number of PspC IgG-secreting BMEM was not different in carriage-positive volunteers 
compared with carriage-negative volunteers (Figure 4A). In both groups the numbers following 
inoculation were comparable to those at baseline. 
At baseline, the number of PspC IgG-secreting BPLAS was not different in carriage-positive volunteers 
compared with carriage-negative volunteers (Figure 4B; 3.2 [1.7-40.6] versus 9.5 [4.1-15.1]). Post 
inoculation, in carriage-positive and carriage-negative volunteers, the number of PspC IgG-secreting 
BPLAS were not significantly different to those at baseline. 
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Baseline number of PS IgG-secreting BMEM are not associated with levels of PS IgG in serum 
Since we observed that a high baseline number of 6BPS IgG-secreting BMEM was associated with 
protection, and that the number of IgG BPLAS were increased following inoculation in carriage 
negative volunteers, we analysed whether the number of 6BPS IgG-secreting BMEM at baseline or the 
number of 6BPS IgG-secreting BPLAS at day 7 were associated with increased levels of 6BPS IgG in 
serum post inoculation.  
Unadjusted linear regression analysis revealed that the baseline number of 6BPS IgG-secreting BMEM 
did not correlate with the area under the curve (AUC) of 6BPS IgG in serum (data not shown). There 
was also no correlation between the increase in 6BPS IgG-secreting BPLAS at day 7 and the AUC of 
6BPS IgG or the absolute number of 6BPS IgG in serum at any time point (data not shown). 
No correlation was observed between the increase in 6BPS IgG BPLAS at any time point or AUC of 
6BPS IgG and colonisation intensity (density and duration; AUC) over the 35 day study period (data 
not shown).  
Baseline number of 6BPS, PspA and PspC IgA-secreting BMEM or BPLAS are not associated with 
protection against carriage acquisition 
At baseline, the number of 6BPS IgA-secreting BMEM and BPLAS were not different in carriage-positive 
volunteers compared with carriage-negative volunteers (Figure S3A). In both groups the numbers of 
6BPS IgA-secreting BMEM and BPLAS following inoculation were comparable to those at baseline. 
At baseline, the number of PspA IgA-secreting BMEM and BPLAS were not significantly different in 
carriage-positive volunteers compared with carriage-negative volunteers (Figure S4A; 2.7 [1.5-4.7] 
versus 3.9 [1.4-4.4] and Figure S2B; 26.9 [5.0-47.5] versus 6.1 [4.2-10.6]). Post-incoulation, in 
carriage-positive and carriage-negative volunteers, the number of PspA IgA-secreting BPLAS were not 
significantly different to those at baseline. 
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At baseline, the number of PspC IgA-secreting BMEM was not different in carriage-positive volunteers 
compared with carriage-negative volunteers (Figure S5A). In both groups the numbers following 
inoculation were comparable to those at baseline.  
At baseline, the number of PspC IgA-secreting BPLAS was higher in carriage-positive volunteers than in 
carriage-negative volunteers (Figure S5B; 46.5 [13.3-103.8] versus 4.1 [3.0-9.4]; P=0.025). Post-
inoculation, in carriage-positive and carriage-negative volunteers, the number of PspC IgA-secreting 
BPLAS were not significantly different to those at baseline.  
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DISCUSSION 
Using our experimental human pneumococcal carriage model and heterologous challenge of 
previously colonized volunteers we have demonstrated that PS-specific, but not protein-specific, B-
cell mediated immunity is associated with protection against carriage acquisition. Specifically, we 
observed that a high number of PS IgG-secreting BMEM rather than PS6B IgG levels was associated 
with protection against carriage. 
It is well established that antibody-mediated immune responses targeting serotype-specific 
polysaccharides protect against pneumococcal disease (17). Serotype replacement, which has been 
observed following the introduction of PCV, highlights the role of PS-mediated immunity in 
protection against carriage (8, 11). We have previously demonstrated 0% carriage acquisition 
following re-challenge with a homologous strain up to 11 months following clearance of the first 
carriage episode (3). Here we demonstrate that heterologous challenge results in a 50% rate of 
carriage, which is similar to the carriage rates observed in our previous studies in which volunteers 
with no current pneumococcal carriage and an unknown history of previous pneumococcal exposure 
were challenged with a 6B strain (3, 11). This supports the hypothesis that PS-specific immunity 
plays an important role in protection against carriage.  
Following on from heterologous challenge experiments, we assessed B-cell mediated PS-specific 
immunity in another cohort of 24 volunteers with no current pneumococcal carriage and an 
unknown history of previous pneumococcal exposure. There was no association between the 
functional capacity of serum antibody, nor number of PspA- or PspC BMEM or BPLAS and protection 
against carriage. We did, however, observe that a high number of circulating PS IgG-secreting BMEM 
at baseline was associated with protection against experimental carriage acquisition.  
Among volunteers protected against carriage, the number of circulating PS IgG-secreting BMEM was 
dramatically reduced and the number of PS-specific IgG-secreting BPLAS increased 7 days post 
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inoculation. Expansion of the PS IgG-secreting BPLAS population was relatively short-lived and 
returned to baseline levels 14 days following inoculation. These data are consistent with a rapid 
differentiation of PS IgG-secreting BMEM into short-lived BPLAS. A similar effect has been observed and 
implicated in immunity to malaria (21).  
Among carriage-negative volunteers, the increased number of circulating PS IgG-secreting BPLAS was 
not accompanied by increased levels of PS IgG in serum or nasal wash. For this reason we 
hypothesise that antibodies produced by these plasma cells bind to the inoculated bacteria in the 
nasopharynx, facilitating bacterial agglutination, impairing bacterial adherence and leading to 
protection from colonisation acquisition. In carriage-positive volunteers, levels of PS IgG and IgA in 
serum were higher at day 14 than at baseline – this response is likely generated through 
immunisation by colonisation rather than an acute response to inoculation. We observed that 
baseline levels of PS IgA in serum were higher in volunteers that were susceptible to colonisation. 
We have previously observed a similar association between susceptibility and increased levels of IgG 
to LytC, PcsB SP0609, SPR0057 and SPR2021 (3). This may be an indication of an underlying 
suceptability to pneumocccal carriage, with elevated serum immunoglobulin indicative of repeated 
exposure. 
While it is well established that repeated exposure to pneumococci is required for the maintenance 
of IgG-secreting BMEM populations, more recently it has been suggested that exposure during life also 
enhances the adult immune response to PCV (22). A similar effect has been observed in the UK, 
where lack of Haemophilus influenzae type B carriage led to an increased incidence of disease 
among children who received a single dose of Hib vaccine(23).  
Based on data presented here, we postulate that: [1] pneumococcal nasal inoculation results in the 
rapid expansion of pre-existing PS-specific BMEM into short-lived IgG-secreting BPLAS. Expansion of BPLAS 
results in increased PS-specific antibody production; these antibodies bind to the inoculated bacteria 
at the nasopharynx resulting in bacterial agglutination and protection from colonisation acquisition. 
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[2] Although pneumococcal colonisation is immunising, adsorption of antibody by bacteria in the 
nasopharynx may prevent the detection of increased antibody production promoted by exposure to 
pneumococcus. [3] Only if colonisation is established BPLAS continue to circulate in high number, 
continued stimulation and antibody production eventually leads to the detection of increased PS-
specific serum IgG as the bacteria are cleared from the nasopharynx. We are currently investigating 
the impact of nasal antibody-mediated agglutination and its role in protection against pneumococcal 
carriage acquisition in PCV vaccinated volunteers. 
IgA plays a prominant role in defence at the mucosal surface; it is involved in controlling invasive 
pneumococcal diseases (24) and the regulation of S. pneumoniae colonisation in the nasal cavity of 
mice (25). We did not observe an association between the number in 6BPS IgA-secreting B-cell 
populations and protection against carriage acquisition, indicating that the peripheral assessment of 
IgA-secreting populations may not reflect the activity of IgA populations at the mucosa. IgA1 
accounts for approximately 90% of all IgA found in peripheral blood and the upper respiratory tract 
(18, 19). Streptococcus pneumoniae is able to cleave IgA1, via IgA1 protease, a mechanism that 
facilitates pneumococcal adherence to the epithelium and abrogates the protective effects of IgA 
(20). As a result, we hypothesise that protection against colonisation was associated with PS IgG-
secreting BMEM populations rather than PS IgA-secreting BMEM populations due to the advantage 
conferred through the generation of IgG rather than IgA based responses.  
The strength of this study is the use of a unique experimental human pneumococcal challenge model 
with multiple assessments of B-cell populations in blood, and antibodies in serum and in nasal wash 
samples; this model allows us to study carriage and its associated immunological responses with a 
known exposure time point. One weakness of this study is that our results propose an important 
mechanism of protection but do not exclude the possibility that other immune cell populations, or 
responses targeting alternate antigens may also contribute towards protection against carriage 
acquisition. 
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Data presented here has important implications for the future of pneumococcal vaccine 
development, as it is likely that PS-mediated immunity is required for high levels of protection 
against carriage acquisition. Several protein-based vaccines are currently in development and it will 
be important to assess whether these vaccines will impact carriage both directly, in immunised 
volunteers, and indirectly, via a herd effect, as observed for PCV vaccines (8, 11, 26). The role of T-
cell responses in the control of carriage density and in clearance of carriage suggests that protein-
based vaccines capable of inducing this type of immunity may offer several advantages over 
currently licensed vaccines, facilitating control of carriage intensity (density and duration), whilst 
maintaining the opportunity for immunisation through natural carriage acquisition (5, 27, 28). 
Specifically, it is possible that protein-based vaccines could prevent pneumonia and invasive 
pneumococcal disease while maintaining the opportunity for further immunisation during natural 
episodes of carriage. We have previously demonstrated the protective effect of PCV-13 on 
pneumococcal carriage (11). We have now demonstrated that PS-mediated naturally acquired 
immunity is a key mediator of protection against carriage acquisition.   
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Figure 1: Kinetics of polysaccharide 6B IgG. IgG specific ELISAs in serum (A) and nasal wash (B) were 
performed against pneumococcal 6B polysaccharide (PS6B). Levels of antibody were determined 
using serum and nasal wash samples from carriage-positive (carriage +) and carriage-negative 
(carriage -) volunteers experimentally inoculated with Streptococcus pneumoniae 6B. Nasal wash 
samples were obtained prior (day -5) and post inoculation (day 7, day 2, day 14 and day 35). Serum 
samples were obtained prior (day -5) and post inoculation (day 7, day 14 and day 35). The box in the 
upper right section shows data collected prior to (day -5) and post (day 14) challenge for those 
volunteers who underwent heterologous challenge (cohort A). Horizontal bars represent median 
values and bars represent the interquartile range.   
Figure 2. Kinetics of polysaccharide 6B IgG-producing B-cell populations. ELISpots were performed 
against pneumococcal polysaccharide 6B (PS6B). The number of IgG-producing memory B-cells 
(BMEM) (A) and plasma cells (BPLAS) (B) were determined using blood samples from carriage-positive 
(carriage +) and carriage-negative (carriage -) volunteers. Samples were obtained prior (day -5) and 
post inoculation (day 7, day 14 and day 35) from healthy volunteers experimentally inoculated with 
Streptococcus pneumoniae 6B. Horizontal bars represent median values and bars represent the 
interquartile range.   
Figure 3. Kinetics of PspA IgG-producing B-cell populations. ELISpots were performed against PspA. 
The number of IgG-producing memory B-cells (BMEM) (A) and plasma cells (BPLAS) (B) were determined 
using blood samples from carriage-positive (carriage +) and carriage-negative (carriage -) volunteers. 
Samples were obtained prior (day -5) and post inoculation (day 7, day 14 and day 35) from healthy 
volunteers experimentally inoculated with Streptococcus pneumoniae 6B. Horizontal bars represent 
median values and bars represent the interquartile range.   
Figure 4. Kinetics of PspC IgG-producing B-cell populations. ELISpots were performed against PspC. 
The number of IgG-producing memory B-cells (BMEM) (A) and plasma cells (BPLAS) (B) were determined 
using blood samples from carriage-positive (carriage +) and carriage-negative (carriage -) volunteers. 
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Samples were obtained prior (day -5) and post inoculation (day 7, day 14 and day 35) from healthy 
volunteers experimentally inoculated with Streptococcus pneumoniae 6B. Horizontal bars represent 
median values and bars represent the interquartile range.   
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Table 1: Participants of heterologous challenge and traditional challenge cohorts 
 
Study 
Number of 
Volunteers 
Age 
(years) 
Sex (M:F) 
Study 
Period 
Dose 
(cfu/naris) 
Experimental 
Carriage Rate 
Cohort A 
(heterologous 
challenge) 
8 28 ± 14 4:4 
Feb 2013 - 
Mar 2013 
35375 ± 2651 50% (4/8) 
Cohort B 
(challenge) 
24 23 ± 3 9:15 
Sep 2012-
Nov 2012 
61944 ± 4603 42% (10/24) 
 
     Table 2: Pre-existing serotypes and carriage status of heterologous challenge cohort (cohort A) 
Subject Serotype Carriage 
Time between carriage episode 
and re-challenge (months) 
1 6 No 14 
2 3 No 11 
3 33 No 9 
4 3 No 13 
5 33 Yes 16 
6 19 Yes 11 
7 15 Yes 14 
8 33 Yes 11 
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Figure 1: Kinetics of polysaccharide 6B IgG. IgG specific ELISAs in serum (A) and nasal wash (B) were 
performed against pneumococcal 6B polysaccharide (PS6B). Levels of antibody were determined using 
serum and nasal wash samples from carriage-positive (carriage +) and carriage-negative (carriage -) 
volunteers experimentally inoculated with Streptococcus pneumoniae 6B. Nasal wash samples were obtained 
prior (day -5) and post inoculation (day 7, day 2, day 14 and day 35). Serum samples were obtained prior 
(day -5) and post inoculation (day 7, day 14 and day 35). The box in the upper right section shows data 
collected prior to (day -5) and post (day 14) challenge for those volunteers who underwent heterologous 
challenge (cohort A). Horizontal bars represent median values and bars represent the interquartile range.    
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Figure 2. Kinetics of polysaccharide 6B IgG-producing B-cell populations. ELISpots were performed against 
pneumococcal polysaccharide 6B (PS6B). The number of IgG-producing memory B-cells (BMEM) (A) and 
plasma cells (BPLAS) (B) were determined using blood samples from carriage-positive (carriage +) and 
carriage-negative (carriage -) volunteers. Samples were obtained prior (day -5) and post inoculation (day 7, 
day 14 and day 35) from healthy volunteers experimentally inoculated with Streptococcus pneumoniae 6B. 
Horizontal bars represent median values and bars represent the interquartile range.    
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Figure 3. Kinetics of PspA IgG-producing B-cell populations. ELISpots were performed against PspA. The 
number of IgG-producing memory B-cells (BMEM) (A) and plasma cells (BPLAS) (B) were determined using 
blood samples from carriage-positive (carriage +) and carriage-negative (carriage -) volunteers. Samples 
were obtained prior (day -5) and post inoculation (day 7, day 14 and day 35) from healthy volunteers 
experimentally inoculated with Streptococcus pneumoniae 6B. Horizontal bars represent median values and 
bars represent the interquartile range.    
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Figure 4. Kinetics of PspC IgG-producing B-cell populations. ELISpots were performed against PspC. The 
number of IgG-producing memory B-cells (BMEM) (A) and plasma cells (BPLAS) (B) were determined using 
blood samples from carriage-positive (carriage +) and carriage-negative (carriage -) volunteers. Samples 
were obtained prior (day -5) and post inoculation (day 7, day 14 and day 35) from healthy volunteers 
experimentally inoculated with Streptococcus pneumoniae 6B. Horizontal bars represent median values and 
bars represent the interquartile range.    
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SUPPLEMENTARY MATERIALS AND METHODS 
Anti-pneumococcal capsular polysaccharide ELISA 
Anti-pneumococcal capsular polysaccharide (PS) antibodies were determined by using the WHO 
internationally standardised method and reagents (16). Briefly, 96-well ELISA plates were coated 
using 5μg/mL of purified 6BPS (Statens Serum Institute) for 5 hours at 37°C. Wells were blocked with 
10% foetal bovine serum in PBS (PBS-F) for 1 hour at 37°C. Plates were washed 3 times with PBS 
containing 0.05% Tween-20 between each step. Samples were diluted in PBS-F containing 10µg/mL 
CWPS Multi (Statens Serum Institute) and incubated for 30 minutes at 37°C. 89-SF5 reference serum 
received from U.S. Food and Drug Administration was used as a standard. Diluted/adsorbed samples 
were then transferred to pre-coated plates and incubated overnight at 4°C. Antibody detection was 
performed as described for anti-pneumococcal protein ELISA. All samples were run in triplicate in 
four dilutions, and samples with a CV of greater than 15% were repeated. Results are expressed as 
µg/mL calculated using the assigned IgG concentrations in reference serum 89-SF5. 
Opsonophagocytic killing assay (OPKA) 
Heat-inactivated serum samples were diluted 1:3, 1:9 and 1:27 in opsonisation buffer B (OBB). A 
control standard was created using heat-inactivated 89SF serum diluted 1:3, 1:9, 1:27, 1:81, 1:243, 
1:729, 1:2,187 and 1/6561 in OBB. Serum and control samples were then added to the wells of a 96-
well U-bottom plate (Costar). Streptococcus pneumoniae 6B were washed, resuspended in Hanks' 
Balanced Salt Solution (HBSS)
+/+
, and added to wells, as required, at concentration of 1 × 10
3
 
cfu/well. Plates were then incubated at 37°C for 20 minutes with shaking (300 r.p.m). 10% 
complement and 1 × 10
5
 THP- 1 cells were added separately to wells, as required (multiplicity of 
infection 100:1 [cells:bacteria]). Plates were then incubated at 37°C for 60 minutes with shaking (300 
r.p.m). 
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Control wells were included which contained THP-1 cells, bacteria and complement, without a 
source of antibody. Additional control wells containing heat-inactivated complement were also 
included. 
Following incubation, plates were placed on ice for 10 minutes. 10µl of the suspension from each 
reaction was then plated in triplicate onto horse blood agar plates (Oxoid). Plates were then 
incubated overnight at 37°C with 5% CO2. The serum killing index was determined by comparing cfu 
recovered from serum treated wells with that from control wells. 
Peripheral blood mononuclear cell (PBMC) isolation 
Peripheral blood samples were collected in lithium heparin Vacutainers
TM
 (BD Biosciences). Samples 
were diluted with an equal volume of Dulbecco's PBS
-/-
 (DPBS; Invitrogen) and PBMCs isolated by 
differential centrifugation using Histopaque®-1077 (Sigma-Aldrich). Cells were washed twice in 
DPBS, re-suspended in complete medium (RPMI-1640 supplemented with 10% FBS and 2% 200mM 
L-glutamine; Invitrogen), and the cell concentration determined using an Improved Neubauer 
Haemocytometer (CamLab). Samples were stored on ice for use in downstream applications. 
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Supplementary Figure Legends 
Supplementary Figure 1. Kinetics of polysaccharide 6B IgA. IgA specific ELISAs in serum (A) and 
nasal wash (B) were performed against pneumococcal 6B polysaccharide (PS6B). Levels of antibody 
were determined using serum and nasal wash samples from carriage-positive (carriage +) and 
carriage-negative (carriage -) volunteers experimentally inoculated with Streptococcus pneumoniae 
6B. Nasal wash samples were obtained prior (day -5) and post inoculation (day 7, day 2, day 14 and 
day 35). Serum samples were obtained prior (day -5) and post inoculation (day 7, day 14 and day 35). 
The box in the upper right section shows data collected prior to (day -5) and post (day 14) challenge 
for those volunteers who underwent heterologous challenge (cohort A). Horizontal bars represent 
median values and bars represent the interquartile range.  
Supplementary Figure 2. Opsonophagocytic activity of serum antibodies at baseline against 6B. 
The functional capacity of antibody against Streptococcus pneumoniae 6B was determined using 
heat-inactivated serum samples from carriage-positive (carriage +) and carriage-negative (carriage -) 
volunteers. The percentage of killing is shown for 3  (1 in 3, 1 in 9 and 1 in 27) . Horizontal bars 
represent median values and bars represent the interquartile range.  
Supplementary Figure 3. Kinetics of polysaccharide 6B IgA-producing B-cell populations. ELISpots 
were performed against pneumococcal polysaccharide 6B (6BPS). The number of IgA-producing 
memory B-cells (BMEM) (A) and plasma cells (BPLAS) (B) were determined using blood samples from 
carriage-positive (carriage +) and carriage-negative (carriage -) volunteers. Samples were obtained 
prior (day -5) and post inoculation (day 7, day 14 and day 35) from healthy volunteers 
experimentally inoculated with Streptococcus pneumoniae 6B. Horizontal bars represent median 
values and bars represent the interquartile range.  
Supplementary Figure 4. Kinetics of PspA IgA-producing B-cell populations. ELISpots were 
performed against PspA. The number of IgA-producing memory B-cells (BMEM) (A) and plasma cells 
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(BPLAS) (B) were determined using blood samples from carriage-positive (carriage +) and carriage-
negative (carriage -) volunteers. Samples were obtained prior (day -5) and post inoculation (day 7, 
day 14 and day 35) from healthy volunteers experimentally inoculated with Streptococcus 
pneumoniae 6B. Horizontal bars represent median values and bars represent the interquartile range.   
Supplementary Figure 5. Kinetics of PspC IgA-producing B-cell populations. ELISpots were 
performed against PspC. The number of IgA-producing memory B-cells (BMEM) (A) and plasma cells 
(BPLAS) (B) were determined using blood samples from carriage-positive (carriage +) and carriage-
negative (carriage -) volunteers. Samples were obtained prior (day -5) and post inoculation (day 7, 
day 14 and day 35) from healthy volunteers experimentally inoculated with Streptococcus 
pneumoniae 6B. Horizontal bars represent median values and bars represent the interquartile range. 
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Supplementary Figure 1. Kinetics of polysaccharide 6B IgA. IgA specific ELISAs in serum (A) and nasal wash 
(B) were performed against pneumococcal 6B polysaccharide (PS6B). Levels of antibody were determined 
using serum and nasal wash samples from carriage-positive (carriage +) and carriage-negative (carriage -) 
volunteers experimentally inoculated with Streptococcus pneumoniae 6B. Nasal wash samples were obtained 
prior (day -5) and post inoculation (day 7, day 2, day 14 and day 35). Serum samples were obtained prior 
(day -5) and post inoculation (day 7, day 14 and day 35). The box in the upper right section shows data 
collected prior to (day -5) and post (day 14) challenge for those volunteers who underwent heterologous 
challenge (cohort A). Horizontal bars represent median values and bars represent the interquartile range.  
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Supplementary Figure 2. Opsonophagocytic activity of serum antibodies at baseline against 6B. The 
functional capacity of antibody against Streptococcus pneumoniae 6B was determined using heat-inactivated 
serum samples from carriage-positive (carriage +) and carriage-negative (carriage -) volunteers. The 
percentage of killing is shown for 3  (1 in 3, 1 in 9 and 1 in 27) . Horizontal bars represent median values 
and bars represent the interquartile range.  
Figure S2  
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Supplementary Figure 3. Kinetics of polysaccharide 6B IgA-producing B-cell populations. ELISpots were 
performed against pneumococcal polysaccharide 6B (6BPS). The number of IgA-producing memory B-cells 
(BMEM) (A) and plasma cells (BPLAS) (B) were determined using blood samples from carriage-positive 
(carriage +) and carriage-negative (carriage -) volunteers. Samples were obtained prior (day -5) and post 
inoculation (day 7, day 14 and day 35) from healthy volunteers experimentally inoculated with 
Streptococcus pneumoniae 6B. Horizontal bars represent median values and bars represent the interquartile 
range.  
Figure S3  
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Supplementary Figure 4. Kinetics of PspA IgA-producing B-cell populations. ELISpots were performed 
against PspA. The number of IgA-producing memory B-cells (BMEM) (A) and plasma cells (BPLAS) (B) were 
determined using blood samples from carriage-positive (carriage +) and carriage-negative (carriage -) 
volunteers. Samples were obtained prior (day -5) and post inoculation (day 7, day 14 and day 35) from 
healthy volunteers experimentally inoculated with Streptococcus pneumoniae 6B. Horizontal bars represent 
median values and bars represent the interquartile range.    
Figure S4  
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Supplementary Figure 5. Kinetics of PspC IgA-producing B-cell populations. ELISpots were performed 
against PspC. The number of IgA-producing memory B-cells (BMEM) (A) and plasma cells (BPLAS) (B) were 
determined using blood samples from carriage-positive (carriage +) and carriage-negative (carriage -) 
volunteers. Samples were obtained prior (day -5) and post inoculation (day 7, day 14 and day 35) from 
healthy volunteers experimentally inoculated with Streptococcus pneumoniae 6B. Horizontal bars represent 
median values and bars represent the interquartile range.  
Figure S5  
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